Tesamorelin vs Sermorelin

Mechanism — both stimulate endogenous GH release

Both compounds are synthetic analogues of human growth-hormone-releasing hormone (GHRH), which binds the GHRH receptor on pituitary somatotrophs to trigger pulsatile GH release. The key difference from exogenous GH (Norditropin, Genotropin): GHRH analogues preserve the natural pulsatile + feedback-regulated GH release pattern, which means lower side-effect risk (insulin resistance, edema, joint pain) than continuous high-dose GH. Sermorelin is GHRH(1-29), the truncated minimum-active fragment of natural GHRH — half-life ~10 minutes, requires daily injection for sustained effect. Tesamorelin is a modified GHRH analogue (trans-3-hexenoyl-GHRH(1-44)) with a fatty acid modification that extends the half-life to ~38 minutes, producing a bigger + longer GH pulse per injection.

• Sermorelin: GHRH(1-29), original GHRH fragment; ~10 min half-life
• Tesamorelin: Modified GHRH(1-44) with fatty acid; ~38 min half-life — bigger GH pulse per dose
• Why GHRH ≠ exogenous GH: Both preserve natural pulsatile GH release + negative feedback; lower side-effect risk than direct GH injection

Efficacy — what trials measured

Tesamorelin: Falutz et al. (2007 NEJM, 412 HIV patients with lipodystrophy) showed 2 mg/day subQ tesamorelin reduced visceral adipose tissue 17-18% over 26 weeks while preserving subcutaneous fat. Follow-up trial confirmed durability over 52 weeks. The visceral-fat reduction is the standout effect — comparable to retatrutide's weight-loss + body-recomp effects but mechanistically different (GH-mediated lipolysis vs incretin-mediated). Sermorelin: data is older + smaller. Walker (2005 Endocrinology) showed sermorelin elevated GH + IGF-1 levels in deficient adults. Multiple anti-aging clinic trials (2010s, mostly open-label) show sermorelin produces similar IGF-1 elevation per unit dose as tesamorelin but requires higher daily doses + longer protocol duration for body-composition effects. Bottom line: tesamorelin has the bigger trial evidence base + stronger body-recomp effect; sermorelin has the longer real-world track record + better safety data in healthy adults.

• Tesamorelin — Falutz 2007: 2 mg/day, 26 wks: -17-18% visceral adipose tissue in HIV lipodystrophy patients
• Tesamorelin durability: 52-wk follow-up: visceral fat reduction maintained
• Sermorelin clinical use: 200-500 mcg/day: raises GH + IGF-1; body-composition effects require longer protocol

Dosing — different ranges + cycle structures

Tesamorelin: standard dose is 2 mg subQ daily (abdomen, before bed to align with natural overnight GH peak). Some research-use protocols cycle 1-2 mg daily 5 days on, 2 off. Reconstitute with BAC water, refrigerate post-recon. Sermorelin: standard dose is 200-500 mcg subQ daily before bed. Higher-end protocols use 1000 mcg daily. Common protocol: 5 days on, 2 off (matches the natural GH pulsatile cycle). Reconstitute with BAC water, refrigerate. Both should be taken before bed because endogenous GH release is pulsatile + peaks during early sleep — GHRH dosing at bedtime amplifies the natural pulse rather than fighting it.

• Tesamorelin: 2 mg subQ daily before bed; 5-on-2-off cycle in research-use
• Sermorelin: 200-500 mcg subQ daily before bed; 5-on-2-off cycle
• Timing: Both before bed — amplifies natural overnight GH peak

Safety — generally clean GHRH-class profile

Both compounds share the GHRH-class safety profile. Most common side effect: injection-site reactions (redness, swelling, mild pain) in 25-40% of users — typically minor. Mild transient flushing in 5-10% of users at higher doses. Theoretical risk: IGF-1 elevation could increase cancer recurrence risk in users with active or recent malignancy — contraindicated. Tesamorelin specifically: post-market data shows mild insulin sensitivity reduction in long-term users (likely from sustained GH/IGF-1 elevation), warranting periodic HbA1c monitoring. Sermorelin: cleaner long-term profile due to shorter half-life + lower per-dose GH spike. Both contraindicated in pregnancy, active malignancy, and pituitary surgery history. Neither causes the carpal tunnel / joint pain / edema that exogenous GH does, because the pulsatile release pattern is preserved.

• Shared common: Injection-site reactions 25-40%; mild transient flushing 5-10%
• Tesamorelin long-term: Mild insulin sensitivity reduction in long-term users; monitor HbA1c quarterly
• Sermorelin long-term: Cleaner profile vs tesamorelin due to shorter half-life
• Shared contraindications: Active malignancy, recent cancer, pregnancy, pituitary surgery history

Cost — significant gap

Tesamorelin: pharmacy retail (Egrifta SV in the US for HIV lipodystrophy) is ~$8,000-12,000/month — heavily indication-restricted. Research-use tesamorelin vials run $30-80 per 10 mg vial in the gray market, putting a daily 2 mg protocol at ~$180-480/month. Sermorelin: compounding pharmacies (legal via telehealth prescription for adult GH support) run $200-400/month for 5000-10000 mcg/month of compound. Research-use sermorelin is dramatically cheaper — $20-50 per 2-5 mg vial, putting a daily 200-500 mcg protocol at $20-60/month. Sermorelin is roughly 5-10× cheaper than tesamorelin at typical dosing on the research-use side.

• Tesamorelin pharmacy: Egrifta SV ~$8,000-12,000/mo — HIV indication only
• Tesamorelin research-use: $180-480/mo at 2 mg/day
• Sermorelin compounded: $200-400/mo via legitimate telehealth (legal Rx)
• Sermorelin research-use: $20-60/mo at 200-500 mcg/day — much cheaper than tesamorelin

Who chooses which

For visceral fat reduction + body recomposition + lipodystrophy: tesamorelin wins on efficacy. The 17-18% visceral fat reduction in Falutz 2007 is the standout result — sermorelin doesn't have equivalent body-recomp trial data. For general healthy-adult GH support, anti-aging protocols, or sleep + recovery optimization: sermorelin is the cost-effective default. The shorter half-life is actually an advantage here — gentler GH pulses, less risk of insulin sensitivity issues, easier to stop without rebound. For users running a peptide stack with other GH-supporting compounds (ipamorelin, CJC-1295): sermorelin is the more common GHRH partner because the gentler effect doesn't oversaturate the receptor. For users specifically targeting belly fat in the context of metabolic syndrome or post-menopausal weight redistribution: tesamorelin's stronger visceral effect justifies the higher cost.